Hsin-Hua Nien1,2, Erich M Sturgis3,4, Merrill S Kies5, Adel K El-Naggar6, William H Morrison2, Beth M Beadle2, Faye M Johnson5,7, Gary B Gunn2, Clifton D Fuller2, Jack Phan2, Kathryn A Gold5, Steven J Frank2, Heath Skinner2, David I Rosenthal2, Adam S Garden2. 1. Department of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Thoracic/Head and Neck Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. The University of Texas Graduate School of Biomedical Sciences, Houston, Texas.
Abstract
BACKGROUND: This was a retrospective study of patients with human papillomavirus (HPV)-associated oropharyngeal cancer treated with concurrent systemic therapy and radiation. METHODS: Data were extracted through chart review, and statistical analyses included frequency tabulation, chi-square, and Kaplan-Meier tests. RESULTS: Three hundred thirty-nine patients were analyzed; 166 received neoadjuvant chemotherapy. One hundred thirty-six patients were treated with cisplatin, 123 with cetuximab, and 59 with carboplatin. The 2-, 3-, and 5-year actuarial overall survival rates were 92%, 88%, and 78%, respectively. There were no significant differences in survival or disease control when analyzed by systemic agent. Platin-treated patients had greater hematologic toxicity, and required more intravenous hydration. The incidence of confluent mucositis was highest among patients treated with cetuximab. CONCLUSION: Platin and cetuximab seem to have similar efficacy when delivered concurrently with radiation in our retrospective population study. Although platin did cause greater hematologic toxicity, radiation-specific side effects seemed relatively comparable.
BACKGROUND: This was a retrospective study of patients with human papillomavirus (HPV)-associated oropharyngeal cancer treated with concurrent systemic therapy and radiation. METHODS: Data were extracted through chart review, and statistical analyses included frequency tabulation, chi-square, and Kaplan-Meier tests. RESULTS: Three hundred thirty-nine patients were analyzed; 166 received neoadjuvant chemotherapy. One hundred thirty-six patients were treated with cisplatin, 123 with cetuximab, and 59 with carboplatin. The 2-, 3-, and 5-year actuarial overall survival rates were 92%, 88%, and 78%, respectively. There were no significant differences in survival or disease control when analyzed by systemic agent. Platin-treated patients had greater hematologic toxicity, and required more intravenous hydration. The incidence of confluent mucositis was highest among patients treated with cetuximab. CONCLUSION:Platin and cetuximab seem to have similar efficacy when delivered concurrently with radiation in our retrospective population study. Although platin did cause greater hematologic toxicity, radiation-specific side effects seemed relatively comparable.
Authors: Shilpa Bhatia; Jaspreet Sharma; Sanjana Bukkapatnam; Ayman Oweida; Shelby Lennon; Andy Phan; Dallin Milner; Nomin Uyanga; Antonio Jimeno; David Raben; Hilary Somerset; Lynn Heasley; Sana D Karam Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: William A Stokes; Whitney A Sumner; Kiersten L Breggren; John T Rathbun; David Raben; Jessica D McDermott; Gregory Gan; Sana D Karam Journal: Rep Pract Oncol Radiother Date: 2017-08-02
Authors: Arya Amini; Megan Eguchi; Bernard L Jones; William A Stokes; Abhinav Gupta; Jessica D McDermott; Erminia Massarelli; Cathy J Bradley; Sana D Karam Journal: Cancer Date: 2018-10-06 Impact factor: 6.860
Authors: Muhammad Furqan; Travis P Snyders; Mohammed U Saqlain; Sarah L Mott; Douglas Laux; Anthony Snow; Carryn M Anderson; John M Watkins; Gerald H Clamon Journal: Cancer Med Date: 2019-04-09 Impact factor: 4.452